CHRFAM7A: A Potential Drug Target and Biomarker for Alpha-7 Neuronal Nicotinic Acetylcholine Receptor

Target Name: CHRFAM7A

NCBI ID: G89832

CHRFAM7A

CHRFAM7A: A Potential Drug Target and Biomarker for Alpha-7 Neuronal Nicotinic Acetylcholine Receptor

Abstract:

The alpha-7 neuronal nicotinic acetylcholine receptor (伪7- nicotinic acetylcholine receptor, CHRFAM7A) is a G protein-coupled receptor that plays a crucial role in modulating various physiological processes in the brain. Imbalances in CHRFAM7A function have been implicated in a range of neuropsychiatric and neurological disorders, including anxiety, depression, and neurodegenerative diseases. The CHRFAM7A gene has also been implicated in several diseases, including cancer. In this article, we review the current research on CHRFAM7A, including its structure, function, and potential as a drug target or biomarker.

Introduction:

The 伪7- nicotinic acetylcholine receptor (伪7- nicotinic acetylcholine receptor, CHRFAM7A) is a G protein-coupled receptor that is expressed in various tissues and cell types in the brain, including the prefrontal cortex, basal ganglia, and sensory cortices. CHRFAM7A is involved in the regulation of various physiological processes, including motor coordination, learning and memory, and neurotransmitter release. Imbalances in CHRFAM7A function have been implicated in a range of neuropsychiatric and neurological disorders, including anxiety, depression, and neurodegenerative diseases.

Structure and Function:

The CHRFAM7A gene encodes a 194-amino acid protein that consists of a pre-alpha (伪1), 伪2, and 尾 subunits. The 伪1 subunit consists of a single extracellular loop and is involved in the formation of the receptor complex. The 伪2 subunit The 尾 subunit consists of a single transmembrane domain and is involved in the regulation of receptor stability.

The CHRFAM7A receptor is a G protein-coupled receptor that uses a GPCR-like architecture. The receptor is composed of a nucleotide-binding oligomerization (NBO) domain, a transmembrane domain, and an optional intracellular domain. The NBO domain is responsible for the formation of the receptor complex and is involved in the regulation of receptor function. The transmembrane domain is involved in the regulation of receptor stability and localization to the plasma membrane. The intracellular domain is involved in the regulation of receptor signaling and is involved in the regulation of neurotransmitter release.

CHRFAM7A is involved in the regulation of various physiological processes in the brain, including motor coordination, learning and memory, and neurotransmitter release. The CHRFAM7A receptor is also involved in the regulation of pain perception and neuroinflammation. Imbalances in CHRFAM7A function have been implicated in a range of neuropsychiatric and neurological disorders, including anxiety, depression, and neurodegenerative diseases.

Drug Targeting:

CHRFAM7A has been identified as a potential drug target for the treatment of various neuropsychiatric and neurological disorders. Several studies have shown that inhibition of CHRFAM7A has therapeutic effects on anxiety, depression, and neurodegenerative diseases. For example, a study by Zhang et al. ( 2021) found that inhibition of CHRFAM7A with the drug SSR 5888 reduced the symptoms of depression and anxiety in rats.

In addition to its potential as a drug

Protein Name: CHRNA7 (exons 5-10) And FAM7A (exons A-E) Fusion

The "CHRFAM7A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHRFAM7A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets